Titan Biotech

Delhi, India Founded: 1992 • Age: 34 yrs Listed
Biological products are manufactured and exported for various industries.
Request Access
Report Incorrect Data
Page last updated

About Titan Biotech

Titan Biotech is a publicly listed company based in Delhi (India) founded in 1992 by Naresh Kumar Singla. Biological products are manufactured and exported for various industries. The company has 467 employees. Its website titanbiotechltd.com draws about 15 thousand monthly visits. Its Indian entity Titan Biotech Limited reported revenue of ₹212 Cr. Titan Biotech offers products and services including Collagen Peptides, Yeast Extract, and Ox Bile Extract Powder. Its focus areas include Food and Agriculture Tech, Crop Tech, Farm Inputs and Biologicals. Its competitors include IPL Biologicals, Univia and Absolute; 3 of its 3 listed competitors have raised funding.

Company details

Titan Biotech was established in 1992 in Delhi, India, as a manufacturer and exporter of biological products. These products are utilized across sectors including pharmaceuticals, nutraceuticals, food and beverages, biotechnology fermentation, cosmetics, veterinary and animal feed, agriculture, microbiology culture media, and plant tissue culture media. Operations focus on supplying materials for industrial applications, with exports extending internationally from the Indian base.

Operational Areas
Agriculture → Crop Tech & Equipment
Key Metrics
  • Market Cap
    ₹1,892 Cr

    TITANBIO · BSE

  • Share Price
    ₹366.40

    +4.81% today

  • Revenue
    ₹206 Cr

    FY 2025-26 · +31.8% YoY

  • EBITDA
    ₹38.60 Cr

    Margin 18.7%

  • Net Profit
    ₹29.88 Cr

    FY 2025-26 · +38.7% YoY

  • P/E (TTM)
    46.4x

    P/B 8.9x

  • ROE
    16.4%

    ROCE 22.5%

  • Debt / Equity
    0.03

    Interest cover 2.7x

  • Employee Count
    467

Products & Services of Titan Biotech

Titan Biotech offers a comprehensive portfolio of products and services, including Collagen Peptides, Yeast Extract, and Ox Bile Extract Powder.

Collagen Peptides
Nutraceuticals

Ingredients for skin and joint care in health products.

Yeast Extract
Food Ingredients

Used in fermentation and food processing applications.

Ox Bile Extract Powder
Pharmaceuticals

Extract for clinical and nutritional formulations.

Board of directors of Titan Biotech Limited (Titan Biotech)

Titan Biotech Limited is the primary company behind Titan Biotech. The board of Titan Biotech Limited currently have 12 directors; the longest-serving is Manju Singla, appointed in 2001. 11 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Manju Singla
DIN 00027790
Director23 Jun 200125 yrs 4 moTitan Biotech Limited
Naresh Singla
DIN 00027448
Managing Director01 May 200224 yrs 6 moTitan Biotech Limited
Supriya Singla
DIN 03526583
Director01 Oct 201214 yrs 1 moTitan Biotech Limited
Suresh Chand Singla
DIN 00027706
Managing Director01 Oct 201214 yrs 1 moTitan Biotech Limited
Rohit Jain
DIN 07191154
Director26 Jul 20215 yrs 3 moTitan Biotech Limited
Raja Singla
DIN 03523719
Whole-time director01 Oct 20224 yrs 1 moTitan Biotech Limited
Abhishek Agarwal
DIN 07286832
Director01 Oct 20224 yrs 1 moTitan Biotech Limited
Udit Singla
DIN 03526575
Whole-time director01 Oct 20233 yrs 1 moTitan Biotech Limited
Shivom Singla
DIN 03615519
Whole-time director01 Oct 20233 yrs 1 moTitan Biotech Limited
Dhairya Madan
DIN 10284820
Director01 Oct 20233 yrs 1 moTitan Biotech Limited
Brijesh Kumar Singh
DIN 10297977
Director01 Oct 20233 yrs 1 moTitan Biotech Limited
Debendra Kumar Sabat
DIN 00802225
Director13 Aug 20251 yr 2 moTitan Biotech Limited

People of Titan Biotech

2 people are tracked at Titan Biotech (2 in leadership); the tracked headcount is 467.

NameRoleGroup
Naresh Kumar Singla
Co-Founder & MD & CSR Committee MembersLeadership
Suresh Singla
Managing DirectorLeadership
Premium access

Complete people profiles for Titan Biotech

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Titan Biotech

Titan Biotech is a publicly listed company on the BSE with ticker symbol TITANBIO in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date20 Dec 1994
  • Listed onBSE: 524717
  • Listed entityTitan Biotech Limited
  • Exchange sectorHealth technology
  • ISININE150C01029
  • Share price₹398.60 (+0.28% on the day) · 2026-10-14
  • Market capitalisation₹1,642 Cr
  • Price to earnings48.6
  • EPS (diluted, trailing year)₹8.20
  • Dividend yield0.12%
  • Volume (last session)7,963

Financials of Titan Biotech

Exchange-reported figures of Titan Biotech Limited, the listed company behind Titan Biotech (BSE: TITANBIO).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹206 Cr
+31.8% YoY
EBITDA
₹38.60 Cr
+51.8% YoY
Profit After Tax
₹29.88 Cr
+38.7% YoY
Net Worth
₹182 Cr
+18.3% YoY
Total Assets
₹190 Cr
+20.1% YoY
Total Debt
₹5.71 Cr
+104.7% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue20615616414412414279.44
Revenue growth+31.8%-4.6%+13.9%+16.6%-13.1%+79.1%-
EBITDA38.6025.4334.2829.5231.2745.8613.50
EBITDA margin+18.7%+16.3%+20.9%+20.5%+25.3%+32.2%+17.0%
Profit before tax38.1724.3731.5328.1128.9742.7010.41
Net profit29.8821.5424.8524.8421.6930.576.61
Net profit margin+14.5%+13.8%+15.2%+17.3%+17.6%+21.5%+8.3%
EPS (₹)7.2326.0630.0730.0626.2436.718.55
Balance sheet
Total assets19015814312096.6189.7866.70
Net worth18215313311086.2468.7539.19
Total debt5.712.798.308.518.9315.9923.88
Cash & bank1.875.563.294.866.815.451.86
Net working capital63.2264.1660.2155.0453.5449.2736.10
Cash flow
Cash from operations30.4220.1221.1521.1822.0419.086.12
Cash from investing(32.55)(9.85)(20.30)(20.73)(16.44)(4.86)(2.21)
Cash from financing(1.53)(7.98)(2.87)(2.40)(4.10)(10.60)(3.95)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue76.4659.1748.8356.5154.3546.5035.1738.28
Revenue growth (YoY)+40.7%+27.3%+38.8%+47.6%+36.3%+7.9%--
Other income1.721.812.111.261.320.721.381.59
EBITDA15.0112.499.7110.839.328.744.574.85
EBITDA margin+19.6%+21.1%+19.9%+19.2%+17.1%+18.8%+13.0%+12.7%
Depreciation1.331.371.301.271.211.150.841.18
Interest0.280.200.240.260.220.200.080.15
Profit before tax15.1212.7310.2810.569.218.115.035.11
Tax3.803.283.722.702.361.951.271.31
Net profit11.329.456.567.866.856.163.763.80
EPS (₹)3.042.631.6310.329.408.304.905.31
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue20615616414412412269.48
Revenue growth+31.8%-4.6%+13.9%+16.6%+0.9%+76.3%-
EBITDA38.6025.4334.2829.5231.2741.4510.87
EBITDA margin+18.7%+16.3%+20.9%+20.5%+25.3%+33.9%+15.6%
Profit before tax38.1724.3731.5328.1128.9738.778.23
Net profit27.4418.2823.6621.0221.6929.025.73
Net profit margin+13.3%+11.7%+14.4%+14.6%+17.6%+23.7%+8.3%
EPS (₹)6.6422.1128.6425.4426.2434.827.50
Balance sheet
Total assets17915013811696.6177.3256.92
Net worth17114512810686.2465.8237.81
Total debt5.712.798.308.518.9310.2617.86
Cash & bank1.875.562.844.866.815.311.73
Net working capital63.2264.1660.2055.0453.5442.1431.03
Cash flow
Cash from operations30.4220.1221.1521.1822.0417.596.92
Cash from investing(32.55)(9.85)(20.30)(20.73)(16.44)(4.17)(0.94)
Cash from financing(1.53)(7.98)(2.87)(2.40)(4.10)(9.81)(5.87)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue76.4659.1748.8356.5154.3546.5035.1738.28
Revenue growth (YoY)+40.7%+27.3%+38.8%+47.6%+36.3%+7.9%--
Other income1.721.812.111.261.320.721.381.59
Total expenses61.4546.6839.1245.6845.0337.7630.6033.43
EBITDA15.0112.499.7110.839.328.744.574.85
EBITDA margin+19.6%+21.1%+19.9%+19.2%+17.1%+18.8%+13.0%+12.7%
Depreciation1.331.371.301.271.211.150.841.18
Interest0.280.200.240.260.220.200.080.15
Profit before tax15.1212.7310.2810.569.218.115.035.11
Tax3.803.283.722.702.361.951.271.31

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 10 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue76.4659.1748.8356.5154.3546.5035.1738.28
Revenue growth (YoY)+40.7%+27.3%+38.8%+47.6%+36.3%+7.9%--
Other income1.721.812.111.261.320.721.381.59
EBITDA15.0112.499.7110.839.328.744.574.85
EBITDA margin+19.6%+21.1%+19.9%+19.2%+17.1%+18.8%+13.0%+12.7%
Depreciation1.331.371.301.271.211.150.841.18
Interest0.280.200.240.260.220.200.080.15
Profit before tax15.1212.7310.2810.569.218.115.035.11
Tax3.803.283.722.702.361.951.271.31
Net profit11.329.456.567.866.856.163.763.80
EPS (₹)3.042.631.6310.329.408.304.905.31
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue20615616414412414279.44
Revenue growth+31.8%-4.6%+13.9%+16.6%-13.1%+79.1%-
Other income5.413.911.751.940.940.791.06
Total expenses16813113011492.2896.3865.94
Employee cost0.0026.3823.7118.2114.2413.0911.51
EBITDA38.6025.4334.2829.5231.2745.8613.50
EBITDA margin+18.7%+16.3%+20.9%+20.5%+25.3%+32.2%+17.0%
Depreciation4.934.173.332.602.372.221.80
Interest0.910.801.170.750.871.732.35
Profit before tax38.1724.3731.5328.1128.9742.7010.41
Tax10.736.097.877.097.2811.002.57
Net profit29.8821.5424.8524.8421.6930.576.61
Net profit margin+14.5%+13.8%+15.2%+17.3%+17.6%+21.5%+8.3%
EPS (₹)7.2326.0630.0730.0626.2436.718.55
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital8.268.268.268.268.268.268.26
Reserves & surplus17314512510277.9860.4930.93
Shareholders' funds (net worth)18215313311086.2468.7539.19
Minority interest0.000.000.000.000.003.722.35
Secured loans3.672.106.757.009.2611.7213.94
Unsecured loans2.040.691.551.51(0.33)4.279.94
Total debt5.712.798.308.518.9315.9923.88
Total liabilities19015814312096.6189.7866.70
Assets
Gross block88.1580.7571.3352.4648.9745.5140.85
Net block61.6157.2752.0135.8934.9933.6131.16
Capital work in progress1.731.702.5513.293.630.270.07
Investments60.3632.7728.1915.414.030.000.00
Inventories55.7750.8245.5736.1734.6832.5427.98
Sundry debtors22.8318.8218.6621.0116.3618.1011.86
Cash & bank balances1.875.563.294.866.815.451.86
Loans & advances4.774.315.116.275.902.742.51
Total current assets85.2479.5172.6368.3163.7558.8344.21
Total current liabilities22.0215.3512.4213.2710.219.568.11
Net working capital63.2264.1660.2155.0453.5449.2736.10
Total assets19015814312096.6189.7866.70
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash5.132.844.866.815.311.831.87
Net cash from operating activities30.4220.1221.1521.1822.0419.086.12
Net cash from investing activities(32.55)(9.85)(20.30)(20.73)(16.44)(4.86)(2.21)
Net cash from financing activities(1.53)(7.98)(2.87)(2.40)(4.10)(10.60)(3.95)
Net change in cash(3.65)2.29(2.02)(1.95)1.513.62(0.04)
Closing cash1.875.563.294.866.815.451.86
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+31.8%-4.6%+13.9%+16.6%-13.1%+79.1%-
EBITDA growth+51.8%-25.8%+16.1%-5.6%-31.8%+239.7%-
PBT growth+56.6%-22.7%+12.2%-3.0%-32.2%+310.2%+87.9%
Net income growth+38.7%-13.3%+0.0%+14.5%-29.1%+362.5%-
Revenue CAGR (3Y)+12.7%+8.2%+4.9%+21.9%+23.9%+35.4%+14.6%
EBITDA CAGR (3Y)+9.4%-6.7%-9.3%+29.8%+52.0%+87.3%+36.0%
Profitability & leverage
Net income margin+13.3%+11.7%+14.4%+14.6%+17.6%+22.3%+9.9%
Return on capital employed+22.5%+16.7%+24.8%+26.6%+32.7%+59.1%+21.1%
Return on net worth+16.4%+12.7%+19.4%+21.4%+28.0%+58.8%+22.0%
Debt / equity0.030.040.070.090.160.370.67
Long-term debt / equity0.010.010.010.020.060.160.35
Interest cover2.703.763.782.793.013.9620.09
Efficiency & per share
Fixed asset turnover2.442.062.652.842.623.292.04
Inventory turnover3.873.254.014.063.684.703.24
Debtors turnover9.908.358.277.717.179.507.53
EPS (₹)7.2326.0630.0730.0626.2436.718.55
Dividend per share (₹)0.502.002.001.801.501.501.00
Book value per share (₹)43.94185.64161.49133.00104.3683.2147.43
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue76.4659.1748.8356.5154.3546.5035.1738.28
Revenue growth (YoY)+40.7%+27.3%+38.8%+47.6%+36.3%+7.9%--
Other income1.721.812.111.261.320.721.381.59
Total expenses61.4546.6839.1245.6845.0337.7630.6033.43
EBITDA15.0112.499.7110.839.328.744.574.85
EBITDA margin+19.6%+21.1%+19.9%+19.2%+17.1%+18.8%+13.0%+12.7%
Depreciation1.331.371.301.271.211.150.841.18
Interest0.280.200.240.260.220.200.080.15
Profit before tax15.1212.7310.2810.569.218.115.035.11
Tax3.803.283.722.702.361.951.271.31
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue20615616414412412269.48
Revenue growth+31.8%-4.6%+13.9%+16.6%+0.9%+76.3%-
Other income5.413.911.751.940.940.751.02
Total expenses16813113011492.2881.0158.61
Employee cost0.0026.3823.7118.2114.2411.089.07
EBITDA38.6025.4334.2829.5231.2741.4510.87
EBITDA margin+18.7%+16.3%+20.9%+20.5%+25.3%+33.9%+15.6%
Depreciation4.934.173.332.602.372.101.75
Interest0.910.801.170.750.871.331.91
Profit before tax38.1724.3731.5328.1128.9738.778.23
Tax10.736.097.877.097.289.992.04
Net profit27.4418.2823.6621.0221.6929.025.73
Net profit margin+13.3%+11.7%+14.4%+14.6%+17.6%+23.7%+8.3%
EPS (₹)6.6422.1128.6425.4426.2434.827.50
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital8.268.268.268.268.268.268.26
Reserves & surplus16313712097.8377.9857.5629.55
Shareholders' funds (net worth)17114512810686.2465.8237.81
Secured loans3.672.107.177.009.268.6111.00
Unsecured loans2.040.691.131.51(0.33)1.656.86
Total debt5.712.798.308.518.9310.2617.86
Total liabilities17915013811696.6177.3256.92
Assets
Gross block88.1580.7571.3352.4648.9738.6934.79
Net block61.6157.2752.0135.8934.9927.0425.24
Capital work in progress1.731.702.5513.293.630.270.00
Investments49.6624.5023.1811.594.031.271.27
Inventories55.7750.8245.5736.1734.6826.8324.14
Sundry debtors22.8318.8218.6621.0116.3616.1210.54
Cash & bank balances1.875.562.844.866.815.311.73
Loans & advances4.774.315.116.275.901.381.70
Total current assets85.2479.5172.1868.3163.7549.6438.11
Total current liabilities22.0215.3511.9813.2710.217.507.08
Net working capital63.2264.1660.2055.0453.5442.1431.03
Total assets17915013811696.6177.3256.92
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash5.132.844.866.815.311.701.59
Net cash from operating activities30.4220.1221.1521.1822.0417.596.92
Net cash from investing activities(32.55)(9.85)(20.30)(20.73)(16.44)(4.17)(0.94)
Net cash from financing activities(1.53)(7.98)(2.87)(2.40)(4.10)(9.81)(5.87)
Net change in cash(3.65)2.29(2.02)(1.95)1.513.610.11
Closing cash1.875.562.844.866.815.311.73
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+31.8%-4.6%+13.9%+16.6%+0.9%+76.3%-
EBITDA growth+51.8%-25.8%+16.1%-5.6%-24.6%+281.3%-
PBT growth+56.6%-22.7%+12.2%-3.0%-25.3%+371.1%+89.2%
Net income growth+50.1%-22.7%+12.6%-3.1%-25.3%+406.5%-
Revenue CAGR (3Y)+12.7%+8.2%+10.2%+27.5%+28.5%+30.2%+9.8%
EBITDA CAGR (3Y)+9.4%-6.7%-6.1%+39.5%+61.2%+84.7%+25.3%
Profitability & leverage
Net income margin+13.3%+11.7%+14.4%+14.6%+17.6%+23.5%+8.9%
Return on capital employed+23.8%+17.5%+25.7%+27.1%+34.3%+59.7%+18.3%
Return on net worth+17.4%+13.4%+20.2%+21.9%+28.5%+55.5%+17.9%
Debt / equity0.030.040.070.090.130.270.57
Long-term debt / equity0.010.010.010.020.040.110.30
Interest cover2.703.763.782.793.013.3820.94
Efficiency & per share
Fixed asset turnover2.442.062.652.842.823.332.03
Inventory turnover3.873.254.014.064.024.813.15
Debtors turnover9.908.358.277.717.619.197.56
EPS (₹)6.6422.1128.6425.4426.2434.827.50
Dividend per share (₹)0.502.002.001.801.501.501.00
Book value per share (₹)41.35175.63155.43128.38104.3679.6545.76

Competitors of Titan Biotech

Titan Biotech has 3 listed competitors in our database, 3 of them funded. They include IPL Biologicals, Univia and Absolute.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
IPL Biologicals
iplbiologicals.com1994Gurugram, India$4.66M901
Plant nutrition and protection products are manufactured and supplied.
Univia
univia.in2020Ahmedabad, India$237,83852
Agri-input retailers are connected to farmers via a phygital network.
Absolute
absolute.ag2015Gurugram, India$115.9M164
Biological technologies are developed for agriculture, healthcare, and materials science.
Premium access

Detailed competitors of Titan Biotech

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Titan Biotech

The website of Titan Biotech (titanbiotechltd.com) receives about 14.6K visits a month.

  • Monthly visits
    14.6K

    ▲ 37.9% vs previous month

Similar websites

Websites whose visitors overlap most with Titan Biotech. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
titanmedia.in
titanmedia.in
100%
–
mpimpex.co.th
mpimpex.co.th
98%
#1,148,179–
Q Laboratories
qlaboratories.com
89%
5.1K#3,709,140View details
philombios.com
philombios.com
89%
–
IFM Quality Services
ifmqs.com.au
89%
#10,303,221View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 17 similar websites and full traffic analytics for Titan Biotech

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 17 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Crop Tech & Equipment

3 companies that operate in the same segment as Titan Biotech (Crop Tech & Equipment) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Ecozen Solutions
Provider of climate-smart deeptech solutions for renewable energy and sustainable agriculture
2010Pune, Maharashtra, IndiaUSD 76.38 MUSD 56.11 M702
Jain Irrigation Systems
Manufacturer and distributor of irrigation equipment
1963Jalgaon, Maharashtra, IndiaUSD 679.04 M2,764
AgroStar
AgroStar is engaged in providing agricultural products and solutions.
2013Pune, Maharashtra, IndiaUSD 208.82 MUSD 31.86 M1,249
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Titan Biotech

Titan Biotech Standalone December 2024 Net Sales at Rs 38.28 crore, down 16.75% Y-o-Y
Moneycontrol • 1 year ago
Global Pharmaceutical Yeast Powders Market Study 2018-2025: Titan BioTech, Ohly, Kothariyeast
Truthweek • 7 years ago
Global Peptone Market 2018 Outlook, Growing by Top Company are Neogen, Titan Biotech, Fenglin, Solabia, Organotechnie, Guizhou Xinhua, Tatua
Truthweek • 8 years ago
Agar Gum Market 2018: Industry Analysis, Market Share, Trends, Business Strategy and Forecast to 2025 – Titan Biotech Ltd, Central Drug House(P) Ltd., Agar Shallow
ICrowdNewswire • 8 years ago
Premium access

Complete news archive for Titan Biotech

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Titan Biotech

Titan Biotech was founded in 1992.

Titan Biotech is headquartered in Delhi, India. It is registered at Delhi, Delhi, India.

Titan Biotech has 467 employees.

The primary company behind Titan Biotech, Titan Biotech Limited, reported revenue of ₹212 Cr for FY 2026, up 32% year on year.

Titan Biotech was established in 1992 in Delhi, India, as a manufacturer and exporter of biological products. These products are utilized across sectors including pharmaceuticals, nutraceuticals, food and beverages, biotechnology fermentation, cosmetics, veterinary and animal feed, agriculture, microbiology culture media, and plant tissue culture media. Operations focus on supplying materials for industrial applications, with exports extending internationally from the Indian base.

Titan Biotech's top competitors include IPL Biologicals, Univia and Absolute.

Titan Biotech offers Collagen Peptides, Yeast Extract, and Ox Bile Extract Powder.

Yes, Titan Biotech is publicly traded on BSE under the ticker symbol TITANBIO.

Titan Biotech operates through Titan Biotech Limited.

The legal entities of Titan Biotech currently have 14 directors, including Manju Singla, Supriya Singla, Raja Singla and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available